|View printer-friendly version|
|October 04, 2004 5:18 p.m.|
|Teva Announces Approval Of Ribavirin Capsules|
Jerusalem, Israel, October 4, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is expected to begin immediately.